Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

TGA warning for top drug class

Posted 27 June 2024 PM

The TGA has followed in the footsteps of its overseas counterparts and added intestinal obstruction, including ileus, as a potential adverse effect to the Product Information (PI) of all GLP-1 receptor agonists (RAs) available in Australia.

Drugs impacted include Eli Lilly's Trulicty and Mounjaro, Novo Nordisk's semaglutide franchise, Ozempic, Wegovy, and Rybelsus along with its liraglutide-containing meds Saxenda, Victoza, and Xultophy.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.